Display options
Cite
Moradi N, Rashidian A, Nosratnejad S, et al. The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method. Pharmacoecon Open. 2019;3(3):311-319doi: 10.1007/s41669-018-0111-2.
Moradi, N., Rashidian, A., Nosratnejad, S., Olyaeemanesh, A., Zanganeh, M., & Zarei, L. (2019). The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method. PharmacoEconomics - open, 3(3), 311-319. https://doi.org/10.1007/s41669-018-0111-2
Moradi, Najme, et al. "The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method." PharmacoEconomics - open vol. 3,3 (2019): 311-319. doi: https://doi.org/10.1007/s41669-018-0111-2
Moradi N, Rashidian A, Nosratnejad S, Olyaeemanesh A, Zanganeh M, Zarei L. The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method. Pharmacoecon Open. 2019 Sep;3(3):311-319. doi: 10.1007/s41669-018-0111-2. PMID: 30617954; PMCID: PMC6710303.
Copy Download .nbib Format: NLM
Share it on

Pharmacoecon Open. 2019 Sep;3(3):311-319. doi: 10.1007/s41669-018-0111-2.

The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method.

PharmacoEconomics - open

Najme Moradi, Arash Rashidian, Shirin Nosratnejad, Alireza Olyaeemanesh, Marzieh Zanganeh, Leila Zarei

Affiliations

  1. Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. [email protected].
  2. Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  3. Department of Health Economics, Iranian Centre of Excellence in Health Service Management, Tabriz University of Medical Sciences, Tabriz, Iran.
  4. Health Economics Department, National Institute for Health Research, Tehran University of Medical Sciences, Tehran, Iran.
  5. Health Equity Research Centre, Tehran University of Medical Sciences, Tehran, Iran.
  6. Head of Health Insurance Office, Ministry of Health and Medical Education, Tehran, Iran.
  7. Health Policy Research Center, Institute of Heath, Shiraz University of Medical Sciences, Tehran, Iran.

PMID: 30617954 PMCID: PMC6710303 DOI: 10.1007/s41669-018-0111-2

Abstract

BACKGROUND: A limited number of studies have specifically examined the value of quality-adjusted life-years (QALYs) from the patient's perspective.

OBJECTIVE: The goal of this study was to investigate the worth of QALYs from the perspectives of patients with diabetes using health and willingness-to-pay (WTP) measures.

METHODS: A hypothetical treatment characterized by a permanent cure was presented to 149 patients with diabetes in Tehran, Iran, to elicit the monetary value that they attach to QALYs. The QALY gains of the participants were determined using the EuroQol-5 Dimensions, 3 Levels instrument, the visual analogue scale, and the time trade-off method. A mixed closed-ended WTP model supported by an open-ended question was used to ascertain the monetary value of a QALY gained. Finally, we used each respondent's ratio of WTP to QALY gained and the mean of the ratios to estimate the worth of a QALY to all respondents.

RESULTS: In total, 96% of respondents were willing to pay out of pocket for the restoration of full health, whereas 4% exhibited a zero WTP because of an inability to pay. The mean WTP per QALY varied depending on the health measure and discount rate used, ranging from $US1191 to $US5043 in sensitivity analysis, which is equal to 0.23-0.95 of Iran's gross domestic product (GDP) per capita in 2015.

CONCLUSION: Applying the upper limit of the World Health Organization's (WHO) cost-effectiveness threshold (i.e., three times the local GDP per capita) in resource allocation decisions requires caution and investigation, particularly in low- and middle-income countries with limited healthcare resources. To generalize our findings, especially for application to decision making, additional surveys involving more representative samples from different settings are recommended.

References

  1. Health Technol Assess. 1999;3(9):i-iv, 1-164 - PubMed
  2. Br J Dermatol. 1999 Dec;141(6):1067-75 - PubMed
  3. Med Decis Making. 2000 Apr-Jun;20(2):194-206 - PubMed
  4. Diabetes Res Clin Pract. 2000 Oct;50 Suppl 2:S77-84 - PubMed
  5. Community Dent Health. 2000 Jun;17(2):92-6 - PubMed
  6. Health Econ. 2001 Sep;10(6):487-97 - PubMed
  7. Health Econ. 2003 Aug;12(8):609-28 - PubMed
  8. Ann Intern Med. 2004 Jun 1;140(11):972-7 - PubMed
  9. Value Health. 2004 Sep-Oct;7(5):518-28 - PubMed
  10. BMJ. 2004 Oct 23;329(7472):972-5 - PubMed
  11. J Obstet Gynaecol. 2004 Oct;24(7):798-800 - PubMed
  12. Med Decis Making. 2005 Nov-Dec;25(6):655-66 - PubMed
  13. Med Decis Making. 2005 Nov-Dec;25(6):667-77 - PubMed
  14. Appl Health Econ Health Policy. 2005;4(4):201-8 - PubMed
  15. Bull World Health Organ. 2007 Aug;85(8):607-14 - PubMed
  16. Health Econ. 2010 Apr;19(4):422-37 - PubMed
  17. Health Serv Res. 2009 Aug;44(4):1406-23 - PubMed
  18. Pharmacoeconomics. 2009;27(12):1005-16 - PubMed
  19. Med Care. 2011 Mar;49(3):267-72 - PubMed
  20. Clinicoecon Outcomes Res. 2013;5:29-36 - PubMed
  21. Soc Sci Med. 2013 Sep;92:92-104 - PubMed
  22. Eur J Health Econ. 2013 Jul;14 Suppl 1:S53-64 - PubMed
  23. Pharmacoeconomics. 2014 Jan;32(1):75-86 - PubMed
  24. Health Econ. 2015 Oct;24(10):1289-1301 - PubMed
  25. J Res Health Sci. 2014 Summer;14(3):181-6 - PubMed
  26. PLoS One. 2015 Apr 09;10(4):e0122760 - PubMed
  27. Iran Red Crescent Med J. 2016 Feb 13;18(2):e21584 - PubMed
  28. Value Health. 2014 Nov;17(7):A438 - PubMed
  29. Iran J Pharm Res. 2017 Spring;16(2):823-833 - PubMed
  30. Pharmacoeconomics. 2018 Jul;36(7):745-758 - PubMed
  31. JAMA. 1996 Oct 16;276(15):1253-8 - PubMed
  32. Ann Allergy Asthma Immunol. 1998 Feb;80(2):189-94 - PubMed
  33. Health Econ. 1998 Feb;7(1):31-8 - PubMed

Publication Types

Grant support